Live tape
Top 8, mentions 7d13,386TSLA3,041 mentions▲ +0.05SPCX2,592 mentions▲ +0.08GOOGL1,788 mentions▲ +0.03META1,437 mentions▲ +0.05CRWV1,266 mentions▲ +0.04NVDA1,179 mentions▲ +0.07QQQ1,135 mentions▲ +0.05NFLX948 mentions▲ +0.03

Equity · Healthcare

BMRN

NASDAQ

BioMarin Pharmaceutical (BMRN)

$56 +2.46% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 20, 2026
Price · Chart
63 sessions
$80 $50 23 Jul 20 Oct

The line runs $59 on 23 July through $56 on 20 October, on a scale from $50 to $80. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 23 Jul – 20 Oct 2026
Market cap $10.8B
P/E (TTM) 143.6
52-week range $49.67 – $70.23
Avg volume 132.1K

as of Oct 20, 2026

BioMarin Pharmaceutical (BMRN) insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Sep 2026

In the 90 days to 22 Oct 2026, BioMarin Pharmaceutical insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 30 Sep 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 1
Net sold $1.16M
Non-trade filings 2
Date Insider Type Shares Value
02 Sep 2026 Davis George Eric EVP, Chief Legal Officer Sell 17,557 $1.16M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
30 Sep 2026 Friberg Gregory R EVP, Chief R&D Officer Tax withheld 4,086 $245K
10 Sep 2026 Plenge Robert M Director Award 6,140

BioMarin Pharmaceutical (BMRN) reported financials

SEC EDGAR XBRL SEC EDGAR

BioMarin Pharmaceutical reported revenue of $3.2B for the fiscal year ended 31 Dec 2025. Net income over the same period was $348.9M.

Figure Reported Period
Revenue $3.2B 31 Dec 2025 fiscal year
Net income $348.9M 31 Dec 2025 fiscal year
Diluted EPS $1.80 31 Dec 2025 fiscal year
Total assets $11.7B 30 Jun 2026 at period end
Total equity $6.3B 30 Jun 2026 at period end

BioMarin Pharmaceutical (BMRN) earnings

SEC EDGAR

BioMarin Pharmaceutical last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.23; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.23 —
31 Mar 2026 Q1 2026 $0.54 —
31 Dec 2025 FY 2025 $1.80 —
30 Sep 2025 Q3 2025 −$0.16 —
30 Jun 2025 Q2 2025 $1.23 —
31 Mar 2025 Q1 2025 $0.95 —
31 Dec 2024 FY 2024 $2.21 —
30 Sep 2024 Q3 2024 $0.55 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

BioMarin Pharmaceutical (BMRN) institutional holders (13F)

SEC Form 13F SEC EDGAR

13 of the 45 institutional funds we track reported a BioMarin Pharmaceutical position for the quarter ended 30 Jun 2026 — a combined $1.1B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) +7.9% shares 7,616,563 $435.8M
AQR Capital Management Trimmed −25.8% shares 5,699,541 $322.5M
Millennium Management Trimmed −31.2% shares 2,071,816 $118.5M
Citadel Advisors Trimmed −75.1% shares 1,122,408 $64.2M
Balyasny Asset Management Held (±25%) −22.6% shares 1,054,613 $60.3M
Renaissance Technologies Trimmed −55.9% shares 451,871 $25.9M
Man Group Held (±25%) +18.8% shares 367,981 $21.1M
Bridgewater Associates Added +32.9% shares 274,911 $15.7M
Marshall Wace New position 97,300 $5.6M
D. E. Shaw & Co. Trimmed −67.4% shares 92,214 $5.3M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

BioMarin Pharmaceutical (BMRN) fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 260 shares of BioMarin Pharmaceutical failed to deliver (about $16K).

Settlement date Shares failed Notional % of shares out
30 Sep 2026 260 $16K <0.001%
21 Sep 2026 823 $53K <0.001%
18 Sep 2026 23,037 $1.5M 0.012%
17 Sep 2026 861 $56K <0.001%

Congressional trades in BioMarin Pharmaceutical (BMRN)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in BioMarin Pharmaceutical is a sale by Daniel S. Goldman (house, NY), dated 06 Mar 2023.

Date Member Type Amount
06 Mar 2023 filed 17 Apr 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K
25 Mar 2019 filed 15 Apr 2019 David J. Taylor house · Republican–OH Sale $1K–$15K

BioMarin Pharmaceutical (BMRN): frequently asked questions

From live data

Have BioMarin Pharmaceutical insiders bought or sold shares recently?

In the 90 days to 22 Oct 2026, BioMarin Pharmaceutical insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 30 Sep 2025, show no open-market purchase. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold BioMarin Pharmaceutical?

13 of the 45 institutional funds we track reported a BioMarin Pharmaceutical position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has BioMarin Pharmaceutical had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for BioMarin Pharmaceutical is dated 30 Sep 2026, when 260 shares failed to deliver.

When did BioMarin Pharmaceutical last report earnings?

BioMarin Pharmaceutical last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.23; no next date is announced in SEC filings yet.

What exchange is BioMarin Pharmaceutical listed on?

BioMarin Pharmaceutical trades on NASDAQ under the ticker BMRN.

Who is the CEO of BioMarin Pharmaceutical?

Jean Jacques Bienaime leads BioMarin Pharmaceutical (BMRN) as chief executive.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings